CJC-1295 + Ipamorelin UAE | Buy Research-Grade GH Peptide Stack | ≥99% Purity

CJC-1295 Without DAC combined with Ipamorelin is the most widely researched dual growth hormone secretagogue stack in endocrinology science — pairing a GHRH receptor agonist with a selective ghrelin receptor agonist to simultaneously stimulate GH release through two entirely distinct pituitary pathways, producing a synergistic GH secretion response that neither compound can achieve alone. Researchers and institutions across the UAE, Dubai, Abu Dhabi and the wider GCC can source verified, research-grade CJC-1295 Without DAC and Ipamorelin with fast international dispatch and full batch documentation for each compound included.

Bundle Contents: CJC-1295 Without DAC + Ipamorelin

✅ ≥99% Purity Each — HPLC & Mass Spectrometry Verified

✅ Batch-Specific Certificate of Analysis (CoA) for Each Peptide

✅ Sterile Lyophilised Powder | GMP Manufactured

✅ Fast International Dispatch to UAE & GCC

What is CJC-1295 Without DAC?

CJC-1295 Without DAC — also known as Modified GRF(1-29) or Mod GRF 1-29 — is a synthetic analogue of the first 29 amino acids of Growth Hormone-Releasing Hormone (GHRH), with four specific amino acid substitutions that improve its stability against enzymatic degradation compared to native GHRH and Sermorelin. The “Without DAC” designation is important — it distinguishes this compound from CJC-1295 With DAC, which contains a Drug Affinity Complex that dramatically extends half-life by enabling albumin binding.

Without the DAC modification, CJC-1295 has a half-life of approximately 30 minutes — significantly longer than native GHRH (~7 minutes) but far shorter than the DAC form. This shorter duration produces a more physiological pulsatile pattern of GH release rather than the sustained GH elevation associated with CJC-1295 With DAC — making it the preferred form for research examining natural GH pulsatility. It acts exclusively through GHRH receptors (GHRHR) on pituitary somatotroph cells, stimulating GH gene expression and pulsatile GH secretion through the cAMP signalling pathway.

What is Ipamorelin?

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue that acts as a selective agonist at the ghrelin receptor (GHSR-1a) — entirely distinct from the GHRH receptor pathway activated by CJC-1295. It is widely regarded as the most selective GH-releasing peptide in its class, stimulating pulsatile GH release with minimal stimulation of cortisol, prolactin, or ACTH — giving it the cleanest hormonal selectivity profile of any synthetic GH secretagogue currently used in research.

Its selectivity, combined with its well-documented GH-releasing properties and favourable pre-clinical safety profile, has made Ipamorelin the most commonly paired secretagogue for GHRH analogue research protocols. Research institutions across the UAE and GCC studying growth hormone axis biology, metabolic regulation, and endocrinology frequently incorporate Ipamorelin into dual-pathway GH secretion studies.

Why Are CJC-1295 Without DAC and Ipamorelin Studied Together?

The research rationale for combining these two compounds is mechanistically straightforward and well-documented in endocrinology literature — they stimulate GH release through entirely different receptor systems that are naturally designed to work synergistically:

Complementary Receptor Systems: CJC-1295 Without DAC activates GHRH receptors while Ipamorelin activates ghrelin receptors (GHSR-1a). These two receptor systems represent the two primary physiological pathways through which the hypothalamus stimulates pituitary GH release — GHRH through the classic growth hormone axis, and ghrelin through the energy-sensing secretagogue pathway.

Synergistic GH Release: Research has documented that combining a GHRH receptor agonist with a GHSR-1a agonist produces GH secretion responses that exceed the sum of each compound’s individual effects — a synergistic rather than simply additive outcome. Studies use this combination to examine the mechanisms underlying this synergy and what it reveals about how the two GH-stimulating pathways interact at the pituitary level.

Physiological Pulsatility: CJC-1295 Without DAC’s moderate half-life combined with Ipamorelin’s short-acting pulsatile GH stimulation produces a GH release pattern that more closely mirrors the natural episodic GH secretion of the healthy pituitary — making this combination particularly valuable for research examining physiological GH axis dynamics.

Selective Endocrine Profile: Ipamorelin’s minimal cortisol and ACTH stimulation means the combination maintains a relatively clean endocrine selectivity profile — isolating GH axis effects without significant HPA axis interference that could confound experimental results.

What Does Each Peptide Do in Research?

CJC-1295 Without DAC Research Applications: Studies have used CJC-1295 Without DAC to examine GHRH receptor pharmacology, pulsatile GH secretion dynamics, hypothalamic-pituitary axis regulation, and how GHRH receptor stimulation duration affects GH release amplitude and frequency. Its improved stability over native GHRH makes it a more practical research tool for controlled experimental protocols requiring consistent GHRH receptor engagement across multiple time points.

Ipamorelin Research Applications: Studies have used Ipamorelin to examine ghrelin receptor pharmacology, selective GH secretagogue effects on the GH axis, and how GHSR-1a activation influences GH pulsatility parameters. Research has also explored its effects on body composition, bone parameters, and gastrointestinal motility in pre-clinical models — reflecting the ghrelin receptor’s distribution across multiple tissue types beyond the pituitary.

Combined Protocol Research: Studies examining both compounds together have explored how dual-pathway GH axis stimulation influences downstream IGF-1 production, body composition parameters, metabolic rate markers, and bone biology in pre-clinical models — providing a more comprehensive picture of GH axis biology than single-compound studies allow.

All applications listed are research-based only. Neither compound is approved for human therapeutic use.

What Do Studies Say About CJC-1295 Without DAC and Ipamorelin?

The combination of GHRH analogues with GHSR-1a agonists has one of the strongest mechanistic foundations in GH axis research:

Endocrinology research has firmly established the synergistic interaction between GHRH and ghrelin receptor pathways in stimulating pituitary GH release — with studies documenting that co-activation of both receptor systems produces GH secretion responses significantly greater than either pathway alone, reflecting the natural co-regulatory relationship between GHRH and ghrelin in physiological GH pulsatility. CJC-1295 Without DAC studies have characterised the improved stability of the modified GHRH fragment compared to native GHRH and Sermorelin — confirming that the four amino acid substitutions extend functional half-life while maintaining full GHRHR binding activity and pulsatile GH release profile. Ipamorelin selectivity research has consistently validated its minimal HPA axis stimulation compared to other synthetic secretagogues — with studies documenting significantly lower cortisol and ACTH responses than GHRP-2 and GHRP-6 at equivalent GH-releasing doses — establishing it as the preferred GHSR-1a agonist for research requiring clean GH axis selectivity. Pre-clinical body composition studies have examined the combined compound protocol in animal models, with research reporting influences on lean mass, fat distribution, and metabolic parameters under sustained dual-pathway GH stimulation — providing insights into how the GH axis’s two primary activation pathways together regulate downstream tissue effects. Comparative GH axis research has used the CJC-1295 Without DAC / Ipamorelin combination as a reference protocol against which other GH secretagogue combinations and GHRH analogues are benchmarked — reflecting its established status as the most studied dual-pathway GH stimulation protocol in research.

CJC-1295 Without DAC + Ipamorelin vs Other GH Research Combinations

Combination	Mechanisms	GH Pattern	Selectivity	Research Profile
CJC-1295 No DAC + Ipamorelin	GHRHR + GHSR-1a	Pulsatile	Excellent	Most studied
CJC-1295 With DAC + Ipamorelin	GHRHR (sustained) + GHSR-1a	Sustained + pulse	Good	Well-documented
Sermorelin + Ipamorelin	GHRHR + GHSR-1a	Pulsatile	Excellent	Well-documented
Tesamorelin + Ipamorelin	GHRHR (full) + GHSR-1a	Pulsatile	Good	Growing
Hexarelin alone	GHSR-1a + CD36	Pulsatile	Moderate	Well-documented

Product Specifications

Parameter	CJC-1295 Without DAC	Ipamorelin
Type	GHRH Analogue	GH Secretagogue
Receptor	GHRHR	GHSR-1a
Length	29 AA (modified)	5 AA (pentapeptide)
Half-Life	~30 minutes	~2 hours
Purity	≥99%	≥99%
Form	Lyophilised Powder	Lyophilised Powder
Solubility	Sterile / bacteriostatic water	Sterile / bacteriostatic water
Storage	-20°C, protect from light	-20°C, protect from light

Buying CJC-1295 + Ipamorelin in UAE — What’s Included

Every order dispatched to the UAE and GCC includes:

• Individual batch-specific Certificate of Analysis (CoA) for each peptide
• HPLC Chromatogram per compound
• Mass Spectrometry Confirmation
• Sterility & Endotoxin Testing Reports
• Reconstitution Protocols for each peptide
• Technical Research Support

Frequently Asked Questions — CJC-1295 + Ipamorelin UAE

Can I buy CJC-1295 Without DAC and Ipamorelin in the UAE?

Yes. We supply research-grade CJC-1295 Without DAC and Ipamorelin with international dispatch to the UAE, Dubai, Abu Dhabi, Sharjah and across the GCC. All orders include individual documentation for each compound and are packaged to maintain peptide integrity throughout transit. These compounds are supplied strictly for laboratory research use only.

What is the difference between CJC-1295 Without DAC and CJC-1295 With DAC?

The DAC (Drug Affinity Complex) modification enables CJC-1295 to bind albumin in biological systems — dramatically extending its half-life to approximately 7–8 days and producing sustained rather than pulsatile GH elevation. CJC-1295 Without DAC has a half-life of approximately 30 minutes and produces pulsatile GH release that more closely mirrors natural GH secretion patterns. The choice between them depends on whether the research requires pulsatile physiological GH dynamics (Without DAC) or sustained GH axis elevation (With DAC).

Why is Ipamorelin preferred over other GHSR-1a agonists for this research combination?

Ipamorelin’s exceptional selectivity profile — minimal cortisol, prolactin, and ACTH stimulation compared to GHRP-2 and GHRP-6 — makes it the preferred GHSR-1a agonist for research requiring clean GH axis stimulation without significant HPA axis interference. When combined with CJC-1295 Without DAC, this selectivity ensures that observed experimental effects can be more confidently attributed to GH axis activation rather than confounded by cortisol or other stress hormone changes.

What is the synergy between GHRH and ghrelin receptor pathways?

In natural GH axis physiology, both GHRH and ghrelin independently stimulate pituitary GH release — but when both signals arrive simultaneously, the GH response is greater than the sum of each signal alone. This synergy occurs because the two receptor systems activate complementary intracellular signalling pathways in somatotroph cells — GHRHR through cAMP and GHSR-1a through phospholipase C — and their combined activation produces amplified GH gene expression and secretion. Research using CJC-1295 Without DAC and Ipamorelin together examines this fundamental aspect of GH axis regulation.

How are these peptides reconstituted for laboratory use?

Allow each vial to reach room temperature before opening. Add sterile or bacteriostatic water slowly down the vial wall of each peptide separately and swirl gently without shaking. Reconstitute each compound independently according to your research protocol’s concentration requirements. Aliquot and store at -80°C for longer-term use to avoid freeze-thaw degradation.

How quickly is this combination delivered to UAE?

Orders are dispatched promptly via tracked international courier. Delivery to the UAE typically takes 3–5 working days, with packaging designed to maintain peptide stability throughout transit.

Research Disclaimer: CJC-1295 Without DAC and Ipamorelin are supplied exclusively for legitimate scientific research purposes conducted within licensed laboratory environments. These products are not intended for human consumption, self-administration, or any therapeutic application. They must be handled by qualified researchers in compliance with applicable UAE regulations and institutional ethics guidelines. Handling should only be performed by qualified laboratory professionals in controlled research settings with appropriate institutional authorisations in place. By purchasing, you confirm that these compounds will be used solely for approved in-vitro or pre-clinical research purposes.